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Background: In previous studies, productivity losses have been measured specifically due to psoriasis or generally due
to health problems in psoriasis patients. There is no information on the proportion of health related productivity losses
that are due to psoriasis.
The aim of this study was to estimate the proportion of productivity losses due to psoriasis and due to other medical
problems among employed psoriasis patients.
Methods: Patients visiting a tertiary level dermatological clinic during a one-year period due to psoriasis or psoriasis
arthritis, who were employed, were selected to the study. A questionnaire was used to assess productivity losses during
the previous month.
Results: Psoriasis accounted for 38% of the total lost productivity costs. One fifth of patients had been on sick leave
(absenteeism) due to psoriasis and a third of patients worked despite being sick with psoriasis (presenteeism). Men had
higher costs of presenteeism, but the costs of absenteeism due to psoriasis were lower for men than for women.
Conclusions: Productivity losses should be assessed disease specifically to avoid overestimations of the role of the
disease on indirect costs. Our study shows that about a third of the lost productivity costs are due to psoriasis.
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Psoriasis is a chronic inflammatory disease, which generally
affects people of working age [1]. Psoriasis reduces
the ability of patients to work and may cause early
retirement [2,3]. It has been estimated that patients with
moderate to severe psoriasis suffer from a significant
(15–20%) decrease in working ability [4-6].
The direct costs of treating psoriasis are substantial
[7-10]. Indirect costs due to lost productivity have been
estimated to exceed those of direct costs among patients
with psoriasis and other chronic inflammatory diseases
[11-15]. Other studies suggest that indirect costs are
substantial but only contribute around 20–36% of the
total costs [8,9,16-18].
Costs due to presenteeism are considered important
when assessing the overall economic burden of psoriasis
and other chronic diseases [1,17,19-22]. These costs are* Correspondence: atmust@utu.fi
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unless otherwise stated.difficult to determine and were often omitted from
studies in the past, although in the past decade, these
costs have been increasingly included. However, the
methods of measuring presenteeism are not consistent
[1,15,20-22]. Presenteeism in psoriasis patients may
account for around half of the indirect costs of lost
productivity [8,14].
In previous studies [8,14,17,18,23] productivity losses
have been measured specifically due to psoriasis or
generally due to health problems. There is no information
on the proportion of health related productivity losses that
are due to psoriasis.
The aim of this study was to estimate the proportion
of productivity losses due to psoriasis and due to other
medical problems, and to assess the factors affecting
presenteeism and absenteeism costs among employed
psoriasis patients.tral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Patient sample
The sample was based on patients (498) who visited
the Department of Dermatology in Turku University
Hospital (TUH) between 1 October 2009 and 30
September 2010 with a diagnosis of psoriasis (Ps) or
psoriatic arthritis (PsA). In the Finnish healthcare
system, patients with mild psoriasis are treated in
primary health care settings and only moderate to
severe cases are referred to tertiary level hospitals for
further treatment. In practice, all psoriatic arthritis
patients in this study sample also had skin symptoms,
which had been the reason for visiting a dermatological
clinic. These patients were asked to complete a question-
naire. A total of 262 patients completed the questionnaire
(52.6% of the total study sample). The share of patients
with PsA diagnosis was 13% in all patients (498) visiting
TUH and those who completed the questionnaire (262).
Ethical consideration
The ethical committee of The Hospital District of
Southwest Finland approved the study. The patients
received a written description of the sampling procedure
and study purpose, as well as the planned use and storage
of the information they were to provide. This was followed
by a description of the subject’s rights according to the
Helsinki declaration. The patients gave a written consent
to use their medical records for the study.
Questionnaire
Socio-demographic background information (e.g. sex,
age, home municipality, number of people living in the
same household, gross income level per family member),
and disease duration were collected. Patients were asked
to list all possible concomitant diseases. Due to small
number of various concomitant diseases, a dichotomy
was formed as: 0 = no other illnesses, 1 = having at least
one concomitant disease. Subjects were asked to report
whether they were employed, retired, studying or
unemployed, with multiple choices allowed. Of the
sample, 98 patients reported that they were working
during the study period, and comprised the sample
used for this study.
Absenteeism was assessed by asking: “How many
hours during the past 4 weeks have you been away from
work due to psoriasis?” A similar question followed to
assess absenteeism arising from other medical reasons.
Presenteeism was assessed by asking: “How many
hours during the past 4 weeks have you been working
while sick, when you felt that you should have stayed at
home because of your psoriasis?” To quantify the loss of
productivity during the hours a patient worked while
sick, a 100 mm visual analogue scale (VAS) was used, with
0 representing not at all affected and 100 representingaffected extremely much, with the following question:
“Please mark an X on the line, to describe the decrease in
efficacy at work because of your psoriasis, during the
hours in the last 4 weeks that you worked while sick?”
Similar questions were used to determine the amount and
impact of presenteeism due to other medical reasons.
Time costs
All time estimates were computed to hours per year.
The VAS score (mm) of lost productivity for presenteeism
was divided by 100 to indicate the magnitude of lost
productivity during the hours the patient worked while
sick. This was used to multiply the hours per year to give
an estimate of productivity loss due to presenteeism.
To estimate the monetary value of the productivity
loss a time-cost assessment was used. The value of an
hour was estimated using the Human Capital Approach
(HCA). The value was based on the average monthly
income in Finland of €2807 for women and €3422 for
men (Statistics Finland 2011). The monthly income levels
were computed to an hour based on average working
hours (157 hours per month) in Finland for people
working full-time. The gross income per family member,
asked in the questionnaire, was not used for time cost
computations as it could have resulted in underestimation
of costs for patients with many family members. It was
only used in the analyses as a background factor indicating
purchasing power.
Statistical analyses
The statistical evaluation of the data was based on
Student’s t-test for means and chi-square test for
proportions. Patients with missing data were not
included in respective cost estimations and statistical
analyses. Linear and logistic regression models were
used to study the impact of different background
factors on the estimates of lost productivity costs. In
the case of skewed distribution to the left (as in the
total costs of absenteeism, presenteeism and total
productivity losses), natural logarithmic transformation
was used to obtain close to normal distribution, which
was necessary for linear modelling. Logistic and linear
regression models of the productivity costs were studied
with the following background factors: sex (dichotomy:
0 = women, 1 = men), disease duration (in years), con-
comitant diseases (dichotomy: 0 = no other illnesses,
1 = having at least one concomitant disease) and level of
income (per family member). There were no statistically
significant differences between patients with skin symp-
toms only and patients with skin symptoms and arthritis
in any of the analyses made. Thus, these two patient
groups were analysed as one psoriasis group. The use of
different treatments, disease severity and quality of life
were similar and without statistical significance between
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not included in final statistical models.
Results
The employed (n = 98) patients of the study sample were
on average 49 years old, 55% were male and 13% were diag-
nosed to have PsA. During the last 4 weeks, approximately
one fifth of employed patients (19%) had been on sick leave
(absenteeism) due to psoriasis and 28% of patients reported
that they had worked despite being sick with psoriasis
(presenteeism). Psoriasis accounted for 38% of the total
costs due to lost productivity (Table 1).
Absenteeism due to other medical reasons was 2.5 times
more common than absenteeism due to psoriasis (Table 1).
For the patients who reported absenteeism, the estimated
mean annual work time lost due to psoriasis was 306 hours,
corresponding to a mean cost of absenteeism of €6296 per
year and a median cost of €2092 per year.
The estimated presenteeism costs due to psoriasis
were around 50% lower than for presenteeism due to other
medical reasons (Table 1). For the patients who reported
presenteeism due to psoriasis, the estimated mean annual
duration was 391 hours. During these hours, the decrease
in productivity was on average 45% (range 8–85%), which
led to a mean cost estimate of €3605 per year and a median
cost of €1647 for presenteeism.
Men and women had similar basal characteristics
with no statistically significant differences in socio-
demographic background factors, disease severity,
quality of life or treatment strategy. Men worked while
sick due to psoriasis for a longer period of time and had a
greater decrease of productivity than women and
thus, higher costs of presenteeism. However, the costs
of absenteeism due to psoriasis were lower for men
than for women (Table 1). Costs of absenteeism and
presenteeism due to other medical reasons were higher
for men than women (Table 1).Table 1 Annual mean costs (€) of absenteeism and presentee
Absenteeism due to psoriasis
Presenteeism due to psoriasis
Productivity loss due to psoriasis
Absenteeism due to other medical reasons
Presenteeism due to other medical reasons
Productivity loss due to other medical reasons
Absenteeism Total (Due to psoriasis and other medical reasons)
Presenteeism Total (Due to psoriasis and other medical reasons)
Total productivity loss (Due to psoriasis and other medical reasons)
Footnote: Subjects with missing data in any category were excluded from respectiv
up costs.
Productivity loss costs displayed separately due to psoriasis, due to other medical r
p-value representing statistical significance between men and women.In logistic regression models the background variables
studied did not show any significant effect on the likelihood
of a patient reporting absenteeism, presenteeism, or any
productivity loss due to psoriasis. The explanatory effect of
the background variables was very limited, with Negelkerke
R values at 0.07 level in all these models.
In a linear regression model, absenteeism costs due to
psoriasis were significantly higher for women than men
(Table 2). The only statistically significant background
factor affecting presenteeism costs due to psoriasis was
having concomitant diseases (Table 2). Other background
factors did not have a statistically significant effect on
absenteeism or presenteeism costs due to psoriasis
(Table 2).
The linear regression models were subjected to a
sensitivity analysis, in which women’s income level was
gradually increased up to 20% higher. The models showed
that observed differences between sexes were not sensitive
to women’s salary level.
Discussion
The findings from the present study indicate that psoriasis
is not necessarily the major health related reason causing
productivity losses among patients with psoriasis. In this
relatively small sample, other medical reasons produced
two-thirds of the overall productivity losses. In two separate
studies in the US, Schmitt and Ford [14] estimated that the
indirect costs of psoriasis were higher than the estimated
direct costs [7]. In the study by Schmitt and Ford [14] the
productivity losses were estimated at a general level (that is,
assessing productivity losses due to any health problems),
which may have led to overestimating the role of psoriasis
in the productivity loss costs. In the present study, the costs
per patient of lost productivity due to psoriasis were
half of those estimated by Schmitt and Ford [14]. The
costs of productivity loss due to any medical reason
(including psoriasis) were higher than the costs estimatedism by sex
Total Men Women p-values
1105 (5045) 355 (987) 2032 (7419) (p = 0,151)
1037 (2776) 1453 (3441) 535 (1566) (p = 0,123)
2250 (6247) 1857 (3943) 2728 (8283) (p = 0,563)
2494 (6832) 2858 (8165) 2045 (4784) (p = 0,609)
1560 (4036) 1882(4476) 1169 (3446) (p = 0,430)
4172 (8807) 4765 (9702) 3417 (7597) (p = 0,514)
3200 (7944) 2531 (7478) 4011 (8520) (p = 0,432)
2307 (5941) 2829 (7212) 1638 (3748) (p = 0,365)
5409 (10515) 4800 (10272) 6160 (10935) (p = 0,603)
e cost estimations. Thus, total loss estimates may differ from summing
easons and the total productivity loss costs (Standard deviation in parenthesis),
Table 2 Linear regression models for natural logarithmic
transformations (ln 1 + costs) of absenteeism and
presenteeism costs due to psoriasis
Absenteeism Presenteeism
Beta t-stat p= Beta t-stat p=
Male sex -0,609 -2,359 0,040 0,398 1,402 0,180
Income level -0,322 1,243 0,242 -0,410 -1,553 0,140
Disease duration 0,199 0,859 0,569 0,375 1,687 0,111
Concomitant diseases 0,393 1,095 0,299 0,446 2,208 0,042
R2 = 0,4 R2 = 0,38
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costs of lost productivity were only those due to or related
to psoriasis. The proportions of direct and indirect costs
of lost productivity may be shifting towards direct
costs, as more expensive biologic medications are being
increasingly used.
Male patients with psoriasis may consider that psoriasis
is an illness that does not require absenteeism from work,
whereas women may more readily take sick leave. This
conclusion is supported by the findings that male patients
with psoriasis had higher costs of absenteeism due to
other illnesses and higher costs of presenteeism than
women with psoriasis. To our knowledge, there are
no previously reported or observed differences between
genders in productivity losses due to psoriasis. Studies on
other diseases have estimated that presenteeism is more
common for women [25,26] and there are mixed results
for absenteeism [25,27]. The differences between genders
in psoriasis patients may be explained by different attitudes
towards visible lesions or other cosmetic hindrance. The
reluctance of male psoriasis patients to take sick leave
when ill may lead to increased severity and duration of
psoriasis, leading to increased presenteeism. However,
further studies with larger samples are needed to
corroborate our findings.
Concomitant diseases have a significant effect on the
overall wellbeing of patients, and a significant effect on
the costs of lost productivity for patients with psoriasis [18]
and other chronic diseases [12]. In our study, concomitant
diseases significantly increased presenteeism costs, but not
absenteeism or total productivity costs due to psoriasis.
However, the small number of various concomitant
diseases among the study patients did not allow specific
comparisons on which type of concomitant diseases had
the greatest effect on productivity loss costs.
It has been stated that there are 16 popularly used
instruments to estimate presenteeism, hampering compar-
isons between studies using different measurements [20].
In a study where different measures for presenteeism were
evaluated, there was a four-fold difference in cost estimates
between the measures providing the highest and the
lowest cost estimations [28]. A recent study on rheumatoiddisorders found inter-country variation in presenteeism
costs when the same measures and methods are used,
suggesting that findings are not directly transferable
from country to country [27]. Even though, given the
inconsistencies between methods of previous studies,
our study’s results on the proportion of psoriasis of
productivity loss may be somewhat generalizable to
other psoriasis patients regardless of methods used.
However, in general questions of absenteeism, and in
particular of presenteeism may be difficult for the patients
to interpret. This can be pronounced when the questions
are dealing with disease as a whole, instead of specific
symptoms (e.g. itch, arthralgia). This may be a possible
source of bias. On the other hand, in our opinion, patients
should not have difficulties in distinguishing between “due
to psoriasis” and “due to other health related problems”.
The costs of early retirement or unemployment can be
substantial; they were estimated to form 92% of lost
productivity costs due to psoriasis [11]. However, retirement
or unemployment are rarely due only to psoriasis or other
chronic diseases and are likely to be affected by concomi-
tant diseases and other health problems. Our study did not
assess the reasons for retirement or unemployment.
Consequently, any cost estimations of retirement or
unemployment could have resulted in unreliable esti-
mations and probable overestimation of these costs,
and thus they were not included in this study.
Caution is advised when of the costs of lost productivity
are extrapolated into economic burden (20). The HCA
method has been criticized for overestimating the costs,
particularly over time horizons greater than 1 year, as in
early retirement [20]. Furthermore, HCA may not consider
all possible costs that the absence of a worker causes to an
employer, and omits the costs of unemployed and retired
patients [29]. In this study the aim was to estimate the
productivity loss of employed patients, thus omitting the
retired and unemployed was considered valid. The present
study focused on a societal perspective of the productivity
losses, thus the HCA method was used. The losses to
employers may be significantly higher, as costs of reduced
productivity may exceed the salaries of employees. It has
been estimated that losses to employers can be up to three
times the gross salaries of sick listed employees [30].
There is no consensus on the time frames that should
be used in questionnaires to assess productivity loss. A
2-week timeframe has been suggested for presenteeism
cost estimations to minimize recall bias of patients and
improve generalizability [20]. However, a recent review
stated that the scientific research on presenteeism and
absenteeism recall periods is inconclusive, but recom-
mended a 3-month recall period for absenteeism and
a 1-week recall period for presenteeism [29]. However, the
rationale for using different time frames for absenteeism
and presenteeism has been questioned [22].
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efficient treatment of autoimmune diseases, as patients
with few symptoms or low severity perform on a par
with healthy co-workers [19]. It has been suggested that
the high acquisition costs of biological treatments could
be offset by improved work productivity and decreased
need for inpatient and outpatient visits [12,31-33].
However, productivity losses should be assessed specifically
for the disease to avoid overestimations of the role of the
disease on indirect costs of lost productivity. Our study
shows that, for patients with psoriasis treated in a tertiary
clinic, a third of the lost productivity costs are due to
psoriasis. More studies with larger sample sizes and
from other societies are needed to verify the proportion
that psoriasis contributes to overall productivity losses.
Conclusion
Productivity losses are significant in patients with psoriasis.
However, only a third of the productivity losses of psoriasis
patients are due to psoriasis.
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